All-In with Chamath, Jason, Sacks & Friedberg cover image

E43: Innovative venture strategies, Zymergen's implosion, Square acquires Afterpay, future of fintech & more

All-In with Chamath, Jason, Sacks & Friedberg

00:00

Navigating Biotech Investment Risks

This chapter tackles the intricacies of evaluating biotech companies, using Zymergen as a case study for failures in due diligence. The speakers advocate for clearer communication of financial metrics and the pitfalls of FOMO in investment decisions. Emphasizing the need for tangible data over narratives, they call for a shift toward metrics-based evaluation in venture capital.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app